AALL1331; Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467 NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Brief description of study
If you are the parent or guardian of a child diagnosed with B-lymphoblastic leukemia, your child may qualify to participate in a clinical trial investigating treatments with blinatumomab. The main goal of this study is to determine how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed).
Clinical Study Identifier: s15-00970
ClinicalTrials.gov Identifier: NCTs15-00970
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
